The paradox of the low-renin state in diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 10, Issue 11, 1999, Pages 2382-2391

  Price, Deborah A ^a   Porter, Lisa E ^a   Gordon, Michael ^a   Fisher, Naomi D L ^a   De'oliveira, Jose Mario F ^a   Laffel, Lori M B ^a   Passan, Diane R ^a   Williams, Gordon H ^a   Hollenberg, Norman K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOHIPPURIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; INULIN; IRBESARTAN; RENIN;

4 AMINOHIPPURIC ACID CLEARANCE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE TIME EFFECT RELATION; DRUG EFFECT; HORMONE INHIBITION; HUMAN; INULIN CLEARANCE; KIDNEY PERFUSION; KIDNEY PLASMA FLOW; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0032709804     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/asn.v10112382     Document Type: Article

References (64)

1. Christlieb AR, Kaldany A, D'Elia JA: Plasma renin activity and hypertension in diabetes mellitus. Diabetes 25: 969-974, 1976
2. Perez GO, Lespier L, Jacobi J: Hyporeninemia and hypoaldosteronism in diabetes mellitus. Arch Intern Med 137: 852-855, 1977
3. Bjorck S: The renin-angiotensin system in diabetes mellitus: A physiological and therapeutic study. Scand J Urol Nephrol Suppl 126: 1-50, 1990
4. Lush DJ, King JA, Fray JCS: Pathophysiology of low renin syndromes: Sites of renal renin secretory impairment and prorenin overexpresion. Kidney Int 43: 983-999, 1993
5. Weidmann P, Ferrari P, Shaw SG: Renin in diabetes mellitus. In: The Renin-Angiotensin System, edited by Robertson JIS, Nicholls MG, Chapter 75, New York, Raven Press, 1991, pp 75.1-75.26
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
7. Slataper R, Vicknair N, Sadler R, Bakris GL: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 153: 973-980, 1993
8. Lebovitz HE, Viegmann TB, Cnaan A: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int Suppl 45: 150-155, 1994
9. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7-year follow-up study. Arch Intern Med 156: 286-289, 1996
10. Ingelfinger JR, Dzau VJ: Molecular biology of renal injury: Emphasis on the role of the renin-angiotensin system. J Am Soc Nephrol Suppl 2: 9-20, 1991
11. Ichikawa I: Will AngII A1 antagonists be renoprotective in humans? Kidney Int 50: 684-692, 1996
12. Rosenberg ME, Smith LJ, Correa-Rotter R, Hostetter TH: The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 45: 403-410, 1994
13. Kikkawa R, Kitamura E, Fujiwara Y, Haneda M, Shigeta Y: Biphasic alteration of renin-angiotensin-aldosterone system in streptozotocin-diabetic rats. Renal Physiol 9: 187-192, 1986
14. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: Functional immunohistochemical, and molecular biological correlations. Am J Physiol 265: F477-F486, 1993
15. Everett AD, Scott J, Wilfong N, Marino B, Rosenkranz RP, Inagami T, Gomez RA: Renin and angiotensinogen expression during the evolution of diabetes. Hypertension 19: 70-78, 1992
16. Kalinyak JE, Sechi LA, Griffin CA, Don BR, Tavangar K, Kraemer FB, Hoffman AR, Sehambelan M: The renin-angiotensin system in streptozotocin-induced diabetes mellitus in the rat. J Am Soc Nephrol 4: 1337-1345, 1993
17. Ballerman B, Skorecki KL, Brenner BM: Reduced glomerular Ang II receptor density in early untreated diabetes mellitus in the rat. Am J Physiol 247: F110-F116, 1984
18. Wilkes BM: Reduced glomerular angiotensin II receptor density in diabetes mellitus in the rat: Time course and mechanism. Endocrinology 120: 1291-1298, 1987
19. Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthelemy G, Gautret: Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. JPET 265: 826-834, 1993
20. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057, 1979
21. Shoback DM, Williams GH, Hollenberg NK, Davies RO, Moore TJ, Dluhy RG: Endogenous Ang II as a determinant of sodium modulated changes in tissue responsiveness to Ang II in normal man. J Clin Endocrinol Metab 57: 764-770, 1983
22. Lentjes GWM, Florijn KW, Chang PC, van Dam W: Inulin measurement in serum and urine with an autoanalyzer, corrected for glucose interference. Eur J Clin Chem Clin Biochem 32: 625-628, 1994
23. Vallon V, Wead LM, Blantz RC: Renal hemodynamics and plasma and kidney angiotensin II in established diabetes mellitus in rats: Effect of sodium and salt restriction. J Am Soc Nephrol 5: 1761-1767, 1995
24. Vander AJ, Greelhoed GW: Inhibition of renin secretion by Ang II. Proc Soc Exp Biol Med 120: 339-403, 1965
25. De Champlain J, Genest J, Veyrat R, Boucher R: Factors controlling renin release in man. Arch Intern Med 117: 355-363, 1966
26. Bing J: Rapid marked increase in plasma renin in rats treated with inhibitors of the renin system. Acta Pathol Microbiol Scand 81: 376-378, 1973
27. Menard J, Guyene T-T, Chatellier G, Kleinbloesem CH, Bernadet P: Renin release regulation during acute renin inhibition in normal volunteers. Hypertension 18: 257-265, 1991
28. Trujillo A, Eggena P, Barrett J, Tuck M: Renin regulation in type 2 diabetes mellitus: Influence of dietary sodium. Hypertension 13: 200-205, 1989
29. De'Oliveira JM, Price DA, Fisher NDL, Allan DR, McKnight JA, Williams GH, Hollenberg NK: Autonomy of the renin system in type 2 diabetes mellitus: Dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 52: 771-777, 1997
30. Miller JA, Floras JS, Zinman B, Skorecki KL, Logan AG: Effect of hyperglycemia on arterial pressure, plasma renin activity and renal function in early diabetes. Clin Sci 90: 189-195, 1996
31. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, Kahn CR: Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93: 12490-12495, 1996
32. Polonsky KS, Sturis J, Bell GI: Non-insulin-dependent diabetes mellitus: A genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 334: 777-783, 1996
33. Schwartz M, Lewis EJ, Leonard-Martin for The Collaborative Study Group: Renal clinicopathology of type 2 diabetes mellitus (DM) [Abstract]. J Am Soc Nephrol 7: 596A, 1996
34. Gambara V, Mecca G, Remuzzi G, Bertani T: Heterogeneous nature of renal lesions in type 2 diabetes. J Am Soc Nephrol 3: 1458-1466, 1993
35. Parving HH, Gall MA, Skott P, Jorgensen HE, Lokkegaard H, Jorgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41: 758-762, 1992
36. Rocchini AP: Cardiovascular regulation in obesity-induced hypertension. Hypertension Suppl 19: 156-160, 1992
37. Carroll JF, Huang M, Hester RL, Cockrell K, Mizelle HL: Hemodynamic alterations in hypertensive obese rabbits. Hypertension 26: 465-470, 1995
38. Porter LE, Hollenberg NK: Obesity, salt intake, and renal perfusion in healthy humans. Hypertension 32: 144-148, 1998
39. Schmieder RE, Bell AH, Weihprecht H, Messerli FH: How should renal hemodynamic data be indexed in obesity? J Am Soc Nephrol 5: 1709-1713, 1995
40. Hopkins PN, Lifton RP, Hollenberg NK, Jeunemaitre X, Hallouin M-C, Skuppin J, Williams CS, Dluhy RG, Lalouel J-M, Williams RR, Williams GH: Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens 14: 199-207, 1996
41. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH, Myers BD: Development and progression of renal disease in PIMA Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 335: 1636-1642, 1996
42. Hollenberg NK, Williams GH: Abnormal renal function, sodium-volume homeostasis and renin system hypertension: The evolution of the nonmodulator concept. In: Hypertension: Pathophysiology, Diagnosis, and Management, edited by Laragh JH, Brenner BM, New York, Raven Press, 1995, pp 1837-1856
43. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH: The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 95: 948-953, 1995
44. Forrester T, McFarlane N, Bennet F, Wilks R, Puras A, Cooper R, Rotimi C, Durazo R, Tewksbury D, Morrison L: AGT and blood pressure among blacks: Findings from a community survey in Jamaica. J Hypertens 14: 315-321, 1996
45. Umemura S, Nyui N, Tamura K, Hibi K, Yamaguchi S, Nakamaru M, Ishigami T, Yabana M, Kihara M, Inoue S, Ishii M: Plasma AGT concentrations in obese patients. Am J Hypertens 10: 629-633, 1997
46. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS: Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 19: 339-344, 1992
47. Tamura K, Tanimoto K, Ishii M, Murakami K, Fukamizu A: Proximal and core DNA elements are required for efficient AGT promoter activation during adipogenic differentiation. J Biol Chem 268: 15024-15032, 1993
48. Hegele RA, Brunt JH, Connelly PW: Genetic variation on chromosome I and associated with variation in body fat distribution in men. Circulation 92: 1089-1093, 1995
49. Murakami E, Hiwada K, Kokubu T: Effects of insulin and glucagon on production of renin substrate by the isolated rat liver. J Endocrinol 85: 151-153, 1980
50. Cassis LA: Down regulation of the renin-angiotensin system in streptozotocin-diabetic rats. Am J Physiol 262: E105-E109, 1992
51. Williams GH, Dluhy RG, Lifton RP, Moore TJ, Gleason R, Williams R, Hunt SC, Hopkins PN, Hollenberg NK: Nonmodulation as an intermediate phenotype in essential hypertension. Hypertension 20: 788-796, 1992
52. Hollenberg NK, Fisher NDL: Renal circulation and blockade of the renin-angiotensin system: Is angiotensin-converting enzyme inhibition the last word? Hypertension 26: 602-609, 1995
53. Price D, De'Oliveira JM, Fisher ND, Hollenberg NK: Renal hemodynamic response to an Ang II antagonist, eprosartan, in healthy men. Hypertension 30: 240-246, 1997
54. Vora JP, Dolbey J, Dean JD, Thomas D, Williams JD, Owens DR, Peters JR: Renal hemodynamics in newly presenting non-insulin dependent diabetes. Kidney Int 41: 829-835, 1992
55. Nowack R, Raum E, Blum W, Ritz E: Renal hemodynamics in recent onset type 2 diabetes. Am J Kidney Dis 20: 342-347, 1992
56. Ter Wee PM, Donker AB: Pharmacologic manipulation of glomerular function. Kidney Int 45: 417-424, 1994
57. Bank N, Aynedjian HS: Role of EDRF (nitric oxide) in diabetic renal hyperfiltration. Kidney Int 43: 1306-1312, 1993
58. Komers R, Cooper ME: Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: Role of kinins. Am J Physiol 268: F588-F594, 1995
59. Mathis KM, Banks RO: Role of nitric oxide and angiotensin II in diabetes mellitus-induced glomerular hyperfiltration, J Am Soc Nephrol 7: 105-112, 1996
60. Brenner BM, Humes HD: Mechanisms of glomerular ultrafiltration. N Engl J Med 297: 148-154, 1977
61. Tucker BJ, Blantz RC: An analysis of the determination of nephron filtration rate. Am J Physiol 232: F477-F483, 1977
62. Carmines PK, Perry MD, Hazelrig JB, Navir LG: Effect of preglomerular and postglomerular vascular resistance alteration on filtration fraction. Kidney Int Suppl 20: 229-232, 1987
63. Neuringer JR, Brenner BM: Glomerular hypertension: Cause and consequence of renal injury. J Hypertens Suppl 10: 91-97, 1992
64. Jeffers BW, Estacio RO, Reynolds MV, Schrier RW: Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int 52: 473-477, 1997